Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients

N/AUnknownNCT01282060

Association Pour la Recherche en Diabetologie et en Geriatrie986 enrolled

Overview

The purpose of this study is to asses the link between glycaemic balance (summarised by HBA1C LEVEL) and specific causes of death.

The GERODIAB study is the first prospective, longitudinal follow-up cohort study, the main aim of which is to assess the link between glycaemic balance (evaluated on the basis of HbA1c levels) and total mortality at 5 years in diabetic patients aged 70 and over, and suffering from type 2 diabetes. An extension to 10 years is considered given the innovative features of this cohort follow-up procedure. The secondary endpoints are as follows: * To assess the link between glycaemic balance and the mortality rate with specific causes. * To assess the link between glycaemic balance and the onset of or change in diabetes-related complications: cardiovascular diseases, change in renal function, diabetic retinopathy, peripheral neuropathy, perforating ulcer of the foot and acute metabolic complications. * To assess the link between glycaemic balance and nutritional status, the onset of or changes in cognitive disorders and a loss of autonomy. * To specify the role of other cardiovascular risk factors combined with glycaemic balance, in mortality, diabetes-related complications, cognitive disorders and loss of autonomy.

Study Type

OBSERVATIONAL

Enrollment

986

Conditions

Type 2 Diabetes

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with type 2 diabetes, aged 70 and over, * Patient having received medicinal or non-medicinal treatment (in the case of diabetics treated with insulin, the length of time between diagnosis of diabetes and the onset of insulin therapy will be at least 2 years), * Diabetes diagnosed for at least one year, * Patient with autonomy defined by a score greater than or equal to 3/6 on the ADL scale, * Patient who can be monitored during hospital or private consultations over the next 10 years, * Patient who did not refuse to take part in the study after receiving information on the study (Patient Information Leaflet), Patients are monitored in the hospital or private sector throughout France. Exclusion Criteria: * Patient with type 1 diabetes, * Patient with secondary diabetes (mainly corticosteroid-induced), * Patient with a loss of autonomy defined by a score of less than 3/6 on the ADL scale, * Patient who cannot be monitored in the months or years to come, * Patient in an acute situation (transient exclusion criterion), * Patient expressing their refusal to participate in the study.

Outcomes

Primary Outcomes

Link between HbA1c level and the overall mortality rate at 5 years.

The primary endpoint is to assess the link between glycaemic balance (assessed on the basis of the HbA1c level) and the overall mortality rate at 5 years for patients of 70 and over suffering from type 2 diabetes.

Time frame: 5 years

Secondary Outcomes

Link between HbA1c level and specific causes of death.

To assess the link between glycaemic balance (summarised by HbA1c level) and specific causes of death.

Time frame: 5 years

Link between HbA1c level and the onset of or changes in diabetes-related complications

To assess the link between glycaemic balance (summarised by HbA1c) and the onset of or changes in diabetes-related complications: - cardiovascular diseases (coronary failure, heart failure, cerebrovascular accidents, arteriopathy obliterans of the lower limbs), - change in renal function, diabetic retinopathy, peripheral neuropathy, perforating ulcer of the foot, acute metabolic complications (hypoglycaemia, diabetic ketoacidosis, hyperosmolarity).

Time frame: 5 years

Link between HbA1c level and nutritional status.

To assess the link between glycaemic balance and nutritional status.

Time frame: 5 years

Link between HbA1c level and the onset of or changes in cognitive disorders.

To assess the link between glycaemic balance and the onset of or changes in cognitive disorders.

Time frame: 5 years

Link between HbA1c level and loss of autonomy.

To assess the link between glycaemic balance and loss of autonomy.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.